Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

Published: April 2017
No. of Pages: 176
    ReportsandReports

Breast cancer is a malignant neoplasm that begins in the breast tissue, which is made up of glands for milk production called lobules and the ducts that connect the lobules to the nipples. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system (ACS, 2013a).

In 2012 about 1.7 Million new cases of breast cancer were diagnosed globally, making it the most common cancer in women. Previously the majority of these incident cases occurred in developed regions (such as the US, EU and Australia) while less developed countries (including several of the assessed Southeast Asian countries) had lower incidence.

The current market for breast cancer consists of chemotherapies, hormonal therapies and targeted therapies. Herceptin is the gold standard monoclonal antibody (mAb) for the treatment of HER2-positive disease, and is prescribed in nearly all settings. Although it is available in all of the assessed countries, its use is limited in the majority of Southeast Asian countries due to affordability issues, and limitations surrounding the diagnosis of HER2 status.

Furthermore, there is currently a very high unmet need in triple negative breast cancer (TNBC). Treatment has been largely dependent on traditional chemotherapies, which are clinically limited in terms of both efficacy and toxicity. There is therefore a need for more effective treatment options that provide substantial improvement in progression-free survival and overall survival.

In South Korea, Singapore and Taiwan the continued uptake of targeted therapies and other premium branded drugs will contribute to the ACoT. The premium therapies Kadcyla and Perjeta are due to be approved in Indonesia, Thailand, Vietnam and Malaysia during the forecast period. Despite a lower level of expected usage of these drugs in these countries, they will account for a significant share of the market in terms of value due to their superior efficacy and high price.

The report “Breast Cancer Therapeutics in Southeast Asia Markets to 2022 – Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market” provides an introduction to breast cancer, detailing the etiology, tumor characteristics, epidemiology, diagnostic techniques, disease staging and typical prognoses for patients.

In depth, this report provides the following analysis -

  • Provides detailed analysis of the products currently marketed for breast cancer, detailing their key characteristics, including safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, pricing, and overall competitive strength.
  • Provides detailed analysis of the pipeline for breast cancer by stage of development, molecule type, program type, mechanism of action and molecular target. It also analyzes recent clinical trials in this indication by enrollment, duration and failure rate,
  • Analysis of contains market forecasts for the breast cancer market, covering epidemiology, treatment usage patterns, pricing and market size for the 2015–2022 forecast period.
  • Describes the major deals that have taken place in the SEA breast cancer market in recent years.

Scope

The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.

  • Which drugs are used as the standard treatment in each setting of the disease?
  • What are the competitive advantages of the existing novel drugs?
  • Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?

There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.

  • Which molecular targets appear most frequently in the pipeline?
  • There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
  • Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.

  • How do failure rates vary by stage of development, molecule type, and molecular target?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022, growing from $942.3m in 2015 at a CAGR of 16.2%.

  • Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?

Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.

  • How will the annual cost of therapy and market size vary between the eight Southeast Asian markets?
  • What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
  • How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
  • How will the potential launch of biosimilars influence each country?
  • Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
  • Various drivers and barriers will influence the market over the forecast period.
  • What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
  • What factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Published By: GBI Research
Product Code: GBI Research1613


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: